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Abstract
Background: Carcinomas of unknown primary site (CUP) are epithelial malignancies revealed by metastatic
lesions in the absence of any detectable primary tumor. Although they often adopt an aggressive clinical pattern,
their basic biology remains poorly understood. Laboratory research on their biology have been hampered so far
by the absence of cell lines representative of CUPs.
Methods: We attempted xenografts of CUP clinical specimens in immunodeficient mice and subsequent in vitro
culture of transplanted malignant cells. Whenever possible, malignant xenografted or cultured cells were
characterized by microsatellite genotyping, immunohistology, electron microscopy, multifish chromosome
analysis and search of TP 53 gene mutations.
Results: Successful xenografts were achieved in 2 cases out of 4. One of them (Capi1) was lost after 3 passages
whereas the other one (Capi3) has been adapted to in vitro culture and is currently available to the scientific
community with reliable identification based on microsatellite genotyping. Both Capi1 and Capi3 have histological
characteristics of adenocarcinomas and display intense expression of EMA, CEA and cytokeratin 7. Multifish
chromosome analysis demonstrated a translocation involving chromosomes 4 and 21 in both specimens. Distinct
rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon
181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens. Finally,
intense membrane expression of c-kit was recorded in Capi3.
Conclusion: Our data suggest that xenografted tumors can be obtained from a substantial fraction of CUP
clinical specimens. The hypothesis of a preferential association of CUPs with TP 53 mutations of codon 181
deserves further investigations. The Capi3 cell line will be a useful tool for assessment of novel c-kit inhibitors.
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Background
The pathogenesis of the carcinomas of unknown primary
site (CUPs) remains one of the most enigmatic topics in
the field of metastasis research [1,2]. They are defined as
biopsy proven metastases of a malignancy in the absence
of an identifiable primary site after clinical examination,
radiological imaging and biological workup. Although
there is no consensus about their incidence, it is reasona-
ble to estimate that CUPs account for 2–3 % of all newly
diagnosed patients with cancer [2,3]. In all described
series, this disease appears to be extremely aggressive with
a median survival below 9 months [2]. Biological mecha-
nisms underlying the CUP phenomenon remain almost
entirely unknown. With regard to histological characteris-
tics, they are predominantly classified as adenocarcino-
mas (50–70%) or poorly differentiated carcinomas (20–
30%). Only 5–8% are squamous cell carcinomas [3].
Though CUPs comprise a heterogeneous group of
tumours with widely varying natural histories, the clinical
picture of CUP demonstrates common characteristics.
Patients predominantly present with a short history of
non-specific complaints (anorexia, weight loss, etc...). The
primary tumor remains unidentified in most cases
throughout the patient's life [4]. The pattern of metastatic
spread tends to be different in CUPs compared to metas-
tasized known primary tumors. Approximately 30% of
patients with CUP present with three or more organs
involved in contrast with less than 15% in classical meta-
static syndromes [4-6]. With the exception of some treata-
ble subgroups – for example young men with extra-
gonadal germ cell tumors – patients with CUP have a very
poor prognosis [7,8]. In some recent, mostly phase II
studies with patients selected from poor prognostic
groups, a median survival of 8–13 months was reached
[9,10].
Despite these intriguing characteristics and the severity of
the prognosis, biology of CUPs has been poorly investi-
gated. Surprisingly, there are only few in vitro cell lines
representative of this category of tumors. To our knowl-
edge, only one such cell line is available in the American
Type Culture Collection but it is uncharacterized (CRL-
7431). It is worth noting that none of the NCI-60 cell line
panel used for systematic in vitro screening of anti-cancer
compounds at the National Cancer Institute (Develop-
mental Therapeutics Program) is derived from a CUP
[11]. In order to obtain biological material required for
biological and pharmacological investigations of CUPs,
we attempted to create xenografted tumor lines derived
from fresh clinical specimens (biopsies or surgical speci-
mens). Successful xenografts were achieved in 2 cases out
of 4. One of them (Capi1) was lost after only 2 passages
whereas the other one (Capi3) has been adapted to in vitro
culture and is available to the scientific community. We
here report biological characteristics of Capi3 along with
some data on Capi1. Rare mutations of the TP53 gene
were recorded for both Capi1 (exon 5) and Capi3 (exon
9).
Methods
Tumor transplantation in immunodeficient mice
Fragments of tumor biopsies or surgical specimens were
obtained with signed informed consent from 4 patients
and grafted on irradiated Swiss nude (5 Gy) and/or NOD-
SCID mice. Two to six tumor fragments of about 4 mm3
were implanted subcutaneously in the recipient animals.
In vitro culture
A xenografted Capi3 tumor was collected and minced in
small pieces in order to favor the release of tumor cells in
monocellular suspension or under the form of small
clumps. This cell suspension was seeded in RPMI supple-
mented with 20% fetal calf serum in 6-well plates coated
with the PX004 extra-cellular matrix (AbCys, Paris,
France). This matrix is produced by a human malignant
epithelial cell line [12]. Contamination by murine fibrob-
lasts was reduced by short applications of trypsin-EDTA
taking advantage of stronger adherence of malignant epi-
thelial cells to the culture support.
Microsatellite analysis
For fingerprint experiments, DNA has been isolated from
cell pellets using the DNeasy tissue kit (QIAGEN, Hilden,
Germany), according to the manufacturer's instructions.
Microsatellite genotypes have been established using
twelve highly polymorphic dinucleotide microsatellite
markers covering six different chromosome arms (5q, 8p,
17p, 17q, 18p, 18q). The sequences of the primers are
from the Ensembl Genome System website [13]. PCR
were carried out in 20 μL using 0.2 mmol/L dNTP, 0.5U
HotStarTaq polymerase (QIAGEN), and sense primers
labelled with 6-FAM (D5S107, D8S1731, D17S796,
D17S1824, D18S53), HEX (D17S1353, D17S1791,
D17S1873, D17S250, D18S1132) or NED (D8S261,
D18S1127). After a 15-min step at 95°C, 35 cycles of 30
sec at 94°C, 30 sec at 55°C and 30 sec at 72°C, followed
by a 6-min final extension at 72°C, were performed. PCR
products were diluted in formamide containing ROX-
labelled 400 HD size markers (PE Applied Biosystems)
and electrophoresed in 50-cm capillaries containing POP-
6 on an ABI PRISM® 3100 Genetic Analyzer (PE Applied
Biosystems). The apparent sizes of the alleles were ana-
lyzed using the GeneScan Analysis 3.1 software (PE
Applied Biosystems).
Immunohistology
Tissue fragments were paraffin-embedded after fixation in
4% formol-PBS. Tissue sections were stained with anti-
bodies directed to EMA (Epithelial Membranous Antigen,
E29 MoAb, Dako), CEA (carcino-embryonic antigen, pol-BMC Cancer 2007, 7:225 http://www.biomedcentral.com/1471-2407/7/225
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yclonal, Dako), CK7 (OV-TL12.30 MoAb, Dako), CK20
(K020.8 MoAb, Dako), TTF1 (8G763/1 MoAb, Dako),
EGF-R (clone 3C6, Ventana) and c-kit (D117 MoAb,
Dako).
Electron microscopy imaging
Cell pellets were fixed with 1.6 % glutaraldehyde at 4°C,
followed by treatment with osmium tetroxide, then dehy-
drated and embedded in epon resin. Ultrathin sections
were cut on an LKB-III ultra-microtome, stained for con-
trast with uranyl acetate and lead citrate and examined
with a Zeiss EM 902 transmission electron microscope.
Cytogenetics
Metaphase chromosome spreads were obtained using
classical procedures, and standard karyotypic analyzes
were performed after RHG banding and were classified
according to ISCN classification [14]. FISH analysis was
performed using 24 color multifish Vysis probes accord-
ing to manufacturer's instructions (Vysis Downers Grove,
Illinois, USA).
Detection of TP53 gene mutations
Total DNA was extracted from xenografted tumor pieces.
Exons 5 to 9 were amplified by PCR in three segments and
analyzed by denaturing high performance liquid chroma-
tography (DHPLC) followed by direct sequencing of
regions generating abnormal chromatograms [15]. Corre-
sponding PCR products were reamplified using nested
primers and sequenced.
Results
Characteristics of donor patients
Transplantation into immunodeficient mice was
attempted with fragments of tumor biopsy or surgical
pieces from 4 patients. Their main clinical and his-
topathological characteristics are summarized in Table 1.
For all these patients, a primary tumor had remained
undetectable after the initial standard work-up including
chest radiography, abdomino-pelvian ultrasound and CT
scan, mammography for female patients, serum assays of
PSA and β-HCG for male patients. Patient 1 (F, 34) pre-
sented with mediastinal and retroperitoneal lymph node
metastases of a poorly differentiated adenocarcinoma
with high plasma levels of CEA, CA125, CA 19-9 and no
elevation of β-HCG or AFP. No lesions were detected by
gynecological explorations. Despite a partial and transient
response to chemotherapy, the issue was fatal in 3
months. Patient 2 (F, 66) presented with isolated pleural
effusion revealing pleural metastases of a mucinous aden-
ocarcinoma without lesions of lung parenchyma or any
other primary tumor. She was treated by pleural symphy-
sis and chemotherapy. Relapse in the pleura and homola-
teral lung occurred 2 years later with continued
progression despite several lines of chemotherapy. Patient
3 (M, 46) was referred to our hospital for cervical lymph
node metastases of a squamous cell carcinoma without a
detectable primary tumor. He was treated by cervical dis-
section and radiotherapy but relapsed two years later in
the mammary gland and axillary lymph nodes. Mastec-
tomy and node dissection combined to chemotherapy
could not prevent mediastinal extension and fatal issue.
Patient 4 (M, 61) was treated for an isolated femur metas-
tasis of a mucinous adenocarcinoma. After chirurgical
resection, osteosynthesis and local radiotherapy, he
remained in complete remission for 10 months. Then
additional malignant lesions became apparent in the lung
and adrenal gland. This patient is still alive after 3 years of
evolution with slow progression under a third line of
chemotherapy (vinorelbine, carboplatin).
Outcome of xenotransplantations and establishment of 
the Capi3 cell line
As shown in Table 1, mouse transplantation was success-
ful in 2 cases out of four, resulting in the growth of the
Capi1 (patient 1) and Capi3 (patient 4) xenografts. Capi1
was lost after 2 passages. However, it was possible to save
frozen pieces of xenografted tumors. Capi3 xenografted
tumor pieces were collected at passage 2 and tumor cells
were released in vitro by mechanical dissociation. Dis-
persed tumor cells were then seeded for in vitro cultures as
reported in the Methods section. Cell attachment was
readily obtained on PX004 extra-cellular matrix, allowing
slow growth of human epithelial cells mixed with murine
fibroblasts. Beyond passage 5, it was possible to grow
these cells on non-coated ordinary plastic vessels. Subse-
quently a progressive increase in cell growth was
observed. At passage 20, doubling time stabilized at 4
days.
Table 1: Characteristics of donor patients and outcome of mouse transplantation
Gender/Age Site of tumor biopsy Histological diagnosis Outcome of 
xenotransplantation
Patient 1 F 34 skin poorly differentiated 
adenocarcinoma
successful
Patient 2 F 66 pleura mucinous adenocarcinoma unsuccessful
Patient 3 M 46 mammary gland squamous cell carcinoma unsuccessful
Patient 4 M 61 tibial bone mucinous adenocarcinoma successfulBMC Cancer 2007, 7:225 http://www.biomedcentral.com/1471-2407/7/225
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Microsatellite tracking assay linking DNA from patient peripheral blood mononuclear cells (PBMC), tumor surgical specimen  (Surg. Spec.) and xenograft to the in vitro Capi3 cell line Figure 1
Microsatellite tracking assay linking DNA from patient peripheral blood mononuclear cells (PBMC), tumor surgical specimen 
(Surg. Spec.) and xenograft to the in vitro Capi3 cell line.
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Microsatellite genotyping at the successive stages of Capi3 
establishment
Microsatellite analysis was performed on various samples
related to the establishment of Capi3 : DNA from donor
patient peripheral blood mononuclear cells, initial tumor
biopsy, xenografted tumor pieces and cells grown in vitro.
All samples shared identical alleles at the 12 tested loci
indicating that they were derived from a single individual.
The results obtained with 7 markers are shown in Figure
1A. In addition to the bands corresponding to the allele
sizes, the migration profiles of the CAn microsatellite
markers contain extra bands that reflect slippage of Taq
polymerase during PCR (-2 bp bands) and non-templated
addition of an A residue (+1 bp bands). These results
exclude the possibility that cross-contamination occurred
at establishment of the xenograft or during in vitro cell
propagation. In addition, the analysis of polymorphic
markers located at 17p12 (D17S1791) and 17p13.1
(D16S796) where the TP53 gene is located demonstrates
loss of heterozygosity (LOH) (Figure 1B). The fact that
LOH is partial in the surgical specimen is likely due to the
presence of normal cells contaminating the sample; alter-
natively, it may also reflect tumor heterogeneity. Both the
xenograft and the cell line exhibit complete LOH at the
TP53 region, in keeping with the presence of a TP53 muta-
tion in this tumor (see subsequent paragraph).
Histology, immuno-phenotyping and ultrastructure
The Capi1 xenograft was derived from a poorly differenti-
ated carcinoma with a fibrous stroma. The same cellular
morphology was found in the xenograft tissue sections
although without the same stroma. A diagnosis of adeno-
carcinoma was suspected on the basis of morphological
examination and confirmed by Alcian blue staining which
demonstrated intra-cytoplasmic mucin (not shown). The
Capi3 xenograft was derived from a mucinous adenocar-
cinoma with obvious aspects of secretory differentiation.
The same cellular morphology was found in xenograft tis-
sue sections. The expression of 6 protein tumor markers
was investigated by immunohistology on the Capi1 and 3
xenografts and corresponding clinical specimens (see
Table 2). Both xenografted tumor lines had abundant
expression of EMA, CEA and cytokeratin 7 (CK7). CK 20
and TTF1 were negative on all tissue sections related to
Capi1. In contrast, partial expression of these markers was
found in Capi3 material. CK20 was weakly positive in
some cells of the surgical piece whereas it was completely
negative in the xenograft. Conversely, TTF1 was com-
pletely negative in the surgical specimen and weakly pos-
itive in the xenograft. Expression of the tyrosine-kinase
receptors EGF-R and c-kit were investigated in both tumor
lines. EGF-R expression was detected in the Capi1 biopsy
but not in the corresponding xenograft. It was completely
absent in Capi3 material. In contrast, the c-kit receptor
was undetectable in Capi1 tissue sections but abundant in
Capi3 material with a plasma membrane distribution sug-
gesting that it was biologically active (Figure 2). Capi3
cells propagated in vitro were further characterized at the
ultrastructural level (Figure 3). Glandular differentiation
was confirmed by the polarized structure of many cells
with abundant microvillosities at one pole (Figure 3A)
and the observation of numerous clusters of glycogen
granulations. The presence of large vacuoles (Figure 3B)
containing multi-membranous structures suggested aber-
rant processes of autophagy.
Cytogenetics
Very complex karyotypes were obtained in both tumor
lines.
Capi1 was 59–60, XX, add(2)(q14), 
der(4)t(4;21)(pter->q28-q31::q24->q28-
q32;q11), add(5)(p15), +6, +7 × 2, +8 × 2, 
-9 × 2, +11, +15, der(16)dup(16)(p12p13?, 
q22q23?), +der(17), +der(19), 
+der(20)(p11qter), -21, +mar cps.
Capi3 was 49–50, X, -Y, der(1)t(1;9) × 2, 
+2 × 2, der(3)t(3;15)(p23;q11), 
der(3)t(1,3;6), t(4;21)(q32-35; q11), +5, 
+der(5)t(5;21)(q11;q21), der(6)t(6;14), 
ider(6)t(6;18), der(7)t(7;16)(p22;q?), 
der(7)t(6;7;9)(p22;q?), 
der(8)t(8)t(8;10)(p11;p11), -9 × 2, 
der(10)t(10;13)(q10;q10), 
der(11)t(3;11)(q21;q23->q13::q23->pter), 
Table 2: Immunohistological phenotyping of xenografted CUPs and corresponding clinical specimens
Capi1 clinical specimen Capi1 xenograft Capi3 clinical specimen Capi3 xenograft
EMA 90% ++ 100% +++ 100% +++ 90% +++
CEA 100% +++ 100% +++ 100% +++ 100% +++
CK7 100% +++ 100% ++ 100% ++ 100% ++
CK20 negative negative 30% + negative
TTF1 negative negative negative 10% ++
EGF-R 90% ++ negative negative negative
c-kit negative negative 70% + 50% +++
Values correspond to the percentage of positive cells and the staining intensity.BMC Cancer 2007, 7:225 http://www.biomedcentral.com/1471-2407/7/225
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i(12q), -13, +der(15)t(3;15)(p23;q21), 
der(16)(t(16;22?)(q11;q11), 
der(17)t(17;19)(q11;q12); del(18)(q11q23), 
der(20)t(10;20)(p11;q13), 
der(22)t(8;12;22), + mar cps (see Figure 4).
It is noteworthy that a t(4;21) and a loss of both chromo-
somes 9 were observed in the two cell lines.
TP53 gene status in Capi1 and Capi3
In Capi1, a C to G transversion was found at nucleotide
14696 of the TP53 locus (accession number X54156 in
Detection of the c-kit tyrosine-kinase in Capi3 tissue sections Figure 2
Detection of the c-kit tyrosine-kinase in Capi3 tissue sections. Panel A : surgical specimen (× 200). Panel B: xenografted tumor 
(× 100). Note that specific staining is mainly associated with the plasma membrane of malignant cells.
A B
Electron microscopy of Capi3 cells propagated in vitro Figure 3
Electron microscopy of Capi3 cells propagated in vitro. M: microvillosities; V: large vacuole suggestive of aberrant autophagy.
AB
1 μ 1 μ
M
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Genbank), in exon 9, resulting in a change of a threonine
into a serine at codon 312. In Capi3, a G to C transversion
was found at nucleotide 13221, in exon 5, resulting in a
change of an arginine into a proline at codon 181.
Discussion
In this study xenografting was successful for 2 out of 4
CUP specimens. This suggests that there is no real biolog-
ical hindrance opposing successful grafting of CUP cells
on immunodeficient mice. If CUP xenografts and cell
lines remain so rare, it is probably due to a lack of delib-
erate efforts to obtain, preserve and spread this type of
biological resource.
Regarding CK20 and TTF1 expression in Capi3, some dif-
ferences were recorded between the surgical tumor speci-
men and the corresponding xenograft. Thanks to
microsatellite analysis, we can rule out errors in tumor
tracking and state positively that these differences reflect a
genuine biological process, for example a selection of
malignant cells more prone to grow in the murine micro-
environment or a direct influence of this microenviron-
ment on gene expression profile as reported in other
models [16,17]. The same factors probably underlie the
changes in EGF-R expression which is absent in the Capi1
xenograft while it was abundant in the corresponding
clinical specimen.
The karyotypes of both cell lines exhibited very complex
chromosomal rearrangements. This is consistent with a
previous report by Pantou et al. which has shown that
most CUPs – although not all of them – are associated
with massive structural alterations of chromosomes [18].
Additional investigations such as high resolution array
CGH will be required to better understand those complex
rearrangements. One important aim will be to elucidate
the t(4;21) translocation observed in both Capi1 and
Capi3. So far t(4, 21) translocations have been exclusively
reported in hematological malignancies according to the
"Mitelman database of chromosome aberrations in can-
cer", especially in myeloid leukemias [19].
There has been only one previous study on TP 53 muta-
tions in CUPs which analyzed exons 5 to 9 in 23 CUP
specimens and found only 6 tumors with mutations
(26%); a frequency which was lower than expected for
this aggressive type of epithelial malignancy. One of the 6
positive specimens had a mutation at nucleotide 13 221
(Bar-Eli  et al., 1993)[20]. In our own study, the same
nucleotide was mutated in the Capi3 tumor. Both muta-
tions resulted in a missense alteration at codon 181 : Arg
to Leu (Bar-Eli et al.) and Arg to Pro (Capi3) respectively.
Mutations of codon 181 are relatively rare, accounting for
only 59 cases out of 23 544 somatic mutations indexed in
the IARC database (to be compared to 1130 mutations
recorded for codon 175; for details see the "IARC TP 53
mutation data base", release R11, 2006) [21-23]. P53
amino-acid 181 is contained in the DNA-binding domain
but has no direct contact with the DNA in contrast with
residues identified as mutational hot spots. Nevertheless,
functional studies have shown that both Leu181Arg and
Pro181Arg mutations impair the transactivating functions
of TP 53 [24,25]. It would be interesting to investigate
additional CUP specimens to know whether mutations of
codon 181 occur at a relatively high frequency in this cat-
egory of malignancies. A distinct TP 53 mutation was
found at codon 312 (Thr to Ser) in the Capi1 xenograft.
This codon accounts for only 13 cases of somatic muta-
tions recorded in the IARC data base. The affected amino-
acid is outside known functional domains. According to
prediction models, this mutation is not expected to be
deleterious (IARC TP 53 mutation data base, R11, 2006)
[21-23]. No mutation of exon 9 have been reported in the
previous study on TP 53 mutations in CUPs [20].
Intense membrane expression of c-kit was found in Capi3
cells in the xenografted tumor as well as in the surgical
specimen. We and others have found that the c-kit protein
is detected in about 10% of CUP specimens [2,26]. Using
the c-kit tyrosine kinase inhibitor, imatinib mesylate,
remarkable therapeutic results have been achieved in
human malignancies overexpressing a mutated form of c-
kit, especially GISTs. In contrast, this compound has only
limited effects on malignancies expressing a non-mutated
form of c-kit, for example small cell lung carcinomas [27].
However a novel generation of c-kit inhibitors which are
currently under investigation might be efficient on a larger
spectrum of c-kit positive malignancies [28]. From this
perspective, the Capi3 cell line will probably be a useful
target for in vitro assessment of these novel compounds.
Conclusion
This report will encourage other investigators to attempt
establishment of CUP cell lines in order to broaden our
possibilities of laboratory investigations. TP 53 mutations
might be more frequent than initially suspected in this
disease [20]. The hypothesis of a preferential association
of CUPs with mutations of codon 181 deserves further
investigations. Finally, the Capi3 cell line will be a useful
tool for assessment of novel c-kit inhibitors.
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